Clinical Impact of High Throughput Sequencing on Liquid Biopsy in Advanced Solid Cancer
| Autor: | Etienne Gouton, Nausicaa Malissen, Nicolas André, Arnaud Jeanson, Annick Pelletier, Albane Testot-Ferry, Caroline Gaudy-Marqueste, Laetitia Dahan, Emeline Tabouret, Thomas Chevalier, Laurent Greillier, Pascale Tomasini |
|---|---|
| Přispěvatelé: | Hôpital de la Timone [CHU - APHM] (TIMONE), Aix Marseille Université (AMU), Service de dermatologie, vénéreologie et cancérologie cutanée [Hôpital de la Timone - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut de neurophysiopathologie (INP), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Assistance Publique - Hôpitaux de Marseille (APHM) |
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
Lung Neoplasms
MESH: Humans liquid biopsy molecular profiling High-Throughput Nucleotide Sequencing cancer targeted therapy precision oncology [SDV.CAN]Life Sciences [q-bio]/Cancer MESH: Lung Neoplasms [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN] MESH: Cell-Free Nucleic Acids Humans MESH: Liquid Biopsy Cell-Free Nucleic Acids MESH: High-Throughput Nucleotide Sequencing |
| Zdroj: | Current Oncology Current Oncology, 2022, 29 (3), pp.1902-1918. ⟨10.3390/curroncol29030155⟩ Current Oncology; Volume 29; Issue 3; Pages: 1902-1918 |
| ISSN: | 1718-7729 |
| Popis: | International audience; Background: Cancer therapies targeting actionable molecular alterations (AMA) have developed, but the clinical routine impact of high-throughput molecular profiling remains unclear. We present a monocentric experience of molecular profiling based on liquid biopsy in patients with cancer.Methods: Patients included had solid cancer and underwent cfDNA genomic profiling with FoudationOne Liquid CDx (F1LCDx) test, analyzing 324 genes. Primary endpoint was to describe patients with an AMA for whom clinical decisions were impacted by F1LCDx test results.Results: 191 patients were included, mostly with lung cancer (46%). An AMA was found in 52%. The most common molecular alterations were: TP53 (52%), KRAS (14%) and DNMT3 (11%). The most common AMA were: CHEK2 (10%), PIK3CA (9%), ATM (7%). There was no difference in progression-free survival (2.66 months vs. 3.81 months, p = 0.17), overall survival (5.3 months vs. 7.1 months, p = 0.64), or PFS2/PFS1 ratio ≥ 1.3 (20% vs. 24%, p = 0.72) between patients receiving a molecularly matched therapy (MMT) or a non-MMT, respectively. Patients with a MMT had an overall response rate of 19% and a disease control of 32%.Conclusions: Routine cfDNA molecular profiling is feasible and can lead to the access of targeted therapies. However, no notable benefit in patient’s outcomes was shown in this unselected pan-cancer study. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|